Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL473576 | 1.00 | TSHR (0.68) | TSHRSMN1; SMN2KMT2AMEN1HTT | |
| SCHEMBL1073143 | 1.00 | TSHR (0.68) | TSHRSMN1; SMN2KMT2AMEN1HTT | |
| SCHEMBL12670558 | 1.00 | TSHR (0.68) | TSHRSMN1; SMN2KMT2AMEN1HTT | |
| Phosphine SCHEMBL27480220 | 0.98 | TSHR (0.66) | TSHRSMN1; SMN2KMT2AMEN1HTT | |
| SCHEMBL27523343 | 0.90 | TSHR (0.57) | TSHRSMN1; SMN2KMT2AMEN1HTT | |
| SCHEMBL16486901 | 0.89 | MMP12 (0.58) | TSHR | |
| SCHEMBL15587062 | 0.88 | LTB4R (0.59) | TSHRSMN1; SMN2KMT2AHPGDLTB4R | |
| SCHEMBL3254192 | 0.88 | LTB4R (0.59) | TSHRSMN1; SMN2KMT2AHPGDLTB4R | |
| SCHEMBL8826605 | 0.88 | LTB4R (0.59) | TSHRSMN1; SMN2KMT2AHPGDLTB4R | |
| SCHEMBL5007804 | 0.88 | TSHR (0.55) | TSHRSMN1; SMN2KMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| EP-3636807-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | Chugai Seiyaku Kabushiki Kaisha (JP) | 2020-04-15 | — | — | EP | disclosed |
| WO-2019075259-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS | CORNELL UNIVERSITY (US) | 2019-04-18 | — | — | WO | disclosed |
| US-20170298093-A1 | Process for the Preparation of (S)-4-Methyl-N-((S)-1-(((S)-4-Methyl-1-((R)-2-Methyloxiran-2-YL)-1-OXO Pentan-2-YL) Amino)-1-OXO-3-Phenylpropan-2-YL)-2-((S)-2-(2-Morpholinoacetamido)-4-Phenylbutanamido) Pentanamide | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD (IN) | 2017-10-19 | — | — | US | disclosed |
| US-20170158734-A1 | EPOXYKETONE COMPOUNDS FOR ENZYME INHIBITION | CENTRAX INTERNATIONAL, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170101440-A1 | METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-13 | — | — | US | disclosed |
| US-20160215016-A1 | SYNTHESIS OF PEPTIDE EPOXY KETONES | SANDOZ GMBH (AT) | 2016-07-28 | — | — | US | disclosed |
| US-8933018-B2 | Boron containing polybasic bacterial efflux pump inhibitors and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| CN-101671218-B | Alcohol production method by reducing ester or lactone with hydrogen | TAKASAGO PERFUMERY CO LTD | 2014-06-18 | — | — | CN | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| EP-2004603-B1 | POLYMORPHIC AND PSEUDOPOLYMORPHIC FORMS OF TRANDOLAPRILAT, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PRODUCTION AND USE | UNIV ZUERICH (CH) | 2013-10-09 | — | — | EP | disclosed |
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| CN-101671218-A | Alcohol production method by reducing ester or lactone with hydrogen | TAKASAGO PERFUMERY CO LTD | 2010-03-17 | — | — | CN | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| WO-2007113680-A2 | POLYMORPHIC AND PSEUDOPOLYMORPHIC FORMS OF TRANDOLAPRILAT, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PRODUCTION AND USE | AZAD PHARMACEUTICAL INGREDIENTS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY10, P2RY12, P2RY11 | TSHR 1541/4885SMN1; SMN2 4576/4885KMT2A 2966/4885 |
| US-20170298093-A1 | Process for the Preparation of (S)-4-Methyl-N-((S)-1-(((S)-4-Methyl-1-((R)-2-Methyloxiran-2-YL)-1-OXO Pentan-2-YL) Amino)-1-OXO-3-Phenylpropan-2-YL)-2-((S)-2-(2-Morpholinoacetamido)-4-Phenylbutanamido) Pentanamide | PSMA1, PSMA2, PSMA6 | TSHR 4199/4885SMN1; SMN2 26/4885KMT2A 525/4885 |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | TSHR 1564/4885SMN1; SMN2 271/4885KMT2A 1548/4885 |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY12, P2RY11, P2RY10 | TSHR 1363/4885SMN1; SMN2 4563/4885KMT2A 2967/4885 |
| US-20170158734-A1 | EPOXYKETONE COMPOUNDS FOR ENZYME INHIBITION | PSMD10, PSMC1, PSMB10 | TSHR 4650/4885SMN1; SMN2 1323/4885KMT2A 2428/4885 |
| US-20170101440-A1 | METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS | NPR1, EDNRB, NPR3 | TSHR 309/4885SMN1; SMN2 1864/4885KMT2A 4534/4885 |
| US-20160215016-A1 | SYNTHESIS OF PEPTIDE EPOXY KETONES | VIP, PTMS, EPOR | TSHR 3481/4885SMN1; SMN2 2902/4885KMT2A 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.